EU Authorised Representative for Medical Devices and IVDs Across Europe

For manufacturers based outside the European Union, bringing medical devices or in vitro diagnostic devices into the European market involves more than product quality, technical documentation and regulatory preparation. Before a device can be placed on the European market, the manufacturer must appoint an EU Authorized Representative based within the European Union and formally recognised as the manufacturer’s authorised representative. This function is critical under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation as regulators require a responsible local entity to manage communication, supply documentation and assist with compliance obligations when needed. An eu-authorized-representative is far more than just a name printed on a label. The representative acts as the legal presence of a non-EU manufacturer and plays an important role in maintaining market access, regulatory confidence and post-market accountability.

 

 

Why an EU Authorized Representative Is Required

European regulations for medical devices aim to safeguard patients, healthcare providers and users by ensuring every product entering the market has a defined chain of responsibility. If a manufacturer operates outside the European Union, regulators cannot always interact with them as easily as they would with a locally established company. This is where the EU Authorized Representative becomes necessary. The representative provides a formal local presence and serves as the official point of communication for Competent Authorities, Notified Bodies and other regulatory stakeholders.

Without appointing an authorised representative, a non-EU manufacturer cannot legally place medical devices or IVDs on the European market. This requirement applies across a broad spectrum of products, from low-risk devices to advanced diagnostic technologies. This obligation applies before market entry, meaning the representative must be selected early in the compliance journey rather than as a last administrative step. For companies preparing for European distribution, selecting the right EU Authorized Representative for Medical Devices and IVDs can significantly influence registration readiness, document management and long-term regulatory stability.

 

 

The Written Mandate Between Manufacturer and Representative

The relationship between the manufacturer and the EU Authorized Representative must be established through a written mandate. This document outlines the activities the representative is permitted to carry out and confirms the responsibilities of both parties. It is a key compliance document because it sets out the scope of representation, responsibilities, communication duties and actions required if compliance concerns arise.

A vague or poorly prepared mandate can create uncertainty at the worst possible time, especially during an authority request, inspection, complaint review or corrective action. A strong mandate should clearly describe how documents will be made available, how regulatory communication will be handled, how incident information will be shared and what happens if the manufacturer does not meet its duties. For this reason, the mandate should be prepared carefully and reviewed before device registration or market placement begins.

 

 

Label and Packaging Requirements

The name and address of the EU Authorized Representative must appear on the device label, packaging or related product information as required by the applicable regulation. This allows authorities, distributors, healthcare professionals and users to identify the local representative linked to the device. It also reinforces the representative’s role as the official European presence for a manufacturer located outside the European Union.

Accurate labelling is essential because incorrect or missing representative details can lead to compliance issues and possible delays in market access. Manufacturers must ensure that artwork, instructions, declarations and registration data are consistent before product release. If the representative changes, labelling and registration details may also need to be updated in a controlled and timely manner.

 

 

Documentation Review and Availability

One of the important duties of an EU Authorized Representative for Medical Devices and IVDs is to verify that key compliance documents are available and properly prepared. This involves confirming the existence of the EU Declaration of Conformity, ensuring technical documentation is complete and verifying that the appropriate conformity assessment route has been followed based on device type and risk classification.

The representative may also need to hold or have access to copies of technical documentation, declarations and Notified Body certificates. These records must remain accessible for inspection by Competent Authorities for the specified retention period after the last device is marketed. This makes document control a central part of the relationship between manufacturer and representative. Manufacturers should maintain updated records and ensure that the representative can respond quickly if regulators request information.

 

 

Communication With Competent Authorities and Notified Bodies

The EU Authorized Representative serves as the formal communication link between the non-EU manufacturer and European regulatory authorities. If a Competent Authority requests data, samples, technical files or clarification, the representative is responsible for assisting with the response. The representative may also liaise with Notified Bodies when necessary, particularly regarding certification, conformity assessments or corrective measures.

This communication function goes beyond simply passing messages. A dependable representative should understand regulatory requirements, maintain accurate records and ensure responses are delivered within required timelines. Late or incomplete replies can lead to serious consequences, including market limitations or additional regulatory scrutiny. For this reason, manufacturers should work with a representative who has strong regulatory knowledge and clear internal processes.

 

 

Post-Market Surveillance and Incident Support

Medical device compliance does not end after market entry. After a device is in circulation, manufacturers must continuously monitor performance, complaints, incidents and safety indicators. The EU Authorized Representative supports this post-market obligation by promptly forwarding complaints and incident reports to the manufacturer.

This is especially important when information comes from clinicians, patients, users, distributors or authorities. Timely reporting allows the manufacturer to determine whether investigation, reporting, field safety actions or corrective measures are required. A strong representative understands that post-market surveillance is not just paperwork. It plays a key role in patient safety, product enhancement and continued regulatory confidence.

 

 

Registration Responsibilities and EUDAMED

Within European regulatory frameworks, manufacturer and representative details must be registered as necessary. The EU Authorized Representative may support the registration of both the manufacturer and representative information in EUDAMED. Accurate registration helps authorities identify responsible parties, review device information and maintain market oversight.

Manufacturers should prepare complete company details, device information, certificates and declarations before registration activities begin. Any inconsistency between labels, declarations, technical files and registration records can create delays or compliance questions. The representative’s role helps ensure all required information is aligned and accessible when required.

 

 

When the Representative Must Take Action

An EU Authorized Representative also carries responsibilities if the manufacturer does not fulfil regulatory requirements. If serious non-compliance occurs and the manufacturer does not correct the issue, the representative may need to end the mandate and inform relevant authorities and the Notified Body where applicable. This responsibility shows why the role is more than administrative.

The representative holds legal responsibility and cannot overlook serious compliance breaches. Manufacturers should therefore view the representative as a regulatory partner rather than a passive provider. Clear communication, regular document updates and defined responsibilities help avoid misunderstandings and minimise risk throughout the product lifecycle.

 

 

Choosing the Right EU Authorized Representative

Selecting an EU Authorized Representative should be done with care. Manufacturers should look for regulatory competence, experience with medical devices and IVDs, document handling capability, clear response procedures and a strong understanding eu-authorized-representative of European requirements. The representative should effectively handle authority communication, maintain records and guide the manufacturer on practical compliance matters.

Cost should not be the only factor. An ineffective representative may lead to delays, communication gaps and increased risk, whereas a strong representative can support confidence during market entry and beyond. The right choice gives non-EU manufacturers a dependable European presence and supports smoother regulatory management.

 

 

Conclusion

An EU Authorized Representative is essential for non-EU manufacturers that want to place medical devices or IVDs on the European market. The role covers legal representation, document availability, regulatory communication, complaint management, registration assistance and intervention in cases of serious non-compliance. Under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation, appointing an authorised representative is mandatory and must be done before market entry. By choosing a competent EU Authorized Representative for Medical Devices and IVDs, manufacturers can strengthen compliance, support patient safety and build a reliable foundation for long-term access to the European market.